Home > Publications Database > Integrative proteomics highlight presynaptic alterations and c-Jun misactivation as convergent pathomechanisms in ALS > print

001     259239
005     20240612120605.0
024 7 _ |a pmc:PMC10412488
|2 pmc
024 7 _ |a 10.1007/s00401-023-02611-y
|2 doi
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:151947191
|2 altmetric
024 7 _ |a pmid:37488208
|2 pmid
037 _ _ |a DZNE-2023-00740
082 _ _ |a 610
100 1 _ |a Aly, Amr
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Integrative proteomics highlight presynaptic alterations and c-Jun misactivation as convergent pathomechanisms in ALS
260 _ _ |a Heidelberg
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718179924_28346
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease mainly affecting upper and lower motoneurons. Several functionally heterogeneous genes have been associated with the familial form of this disorder (fALS), depicting an extremely complex pathogenic landscape. This heterogeneity has limited the identification of an effective therapy, and this bleak prognosis will only improve with a greater understanding of convergent disease mechanisms. Recent evidence from human post-mortem material and diverse model systems has highlighted the synapse as a crucial structure actively involved in disease progression, suggesting that synaptic aberrations might represent a shared pathological feature across the ALS spectrum. To test this hypothesis, we performed the first comprehensive analysis of the synaptic proteome from post-mortem spinal cord and human iPSC-derived motoneurons carrying mutations in the major ALS genes. This integrated approach highlighted perturbations in the molecular machinery controlling vesicle release as a shared pathomechanism in ALS. Mechanistically, phosphoproteomic analysis linked the presynaptic vesicular phenotype to an accumulation of cytotoxic protein aggregates and to the pro-apoptotic activation of the transcription factor c-Jun, providing detailed insights into the shared pathobiochemistry in ALS. Notably, sub-chronic treatment of our iPSC-derived motoneurons with the fatty acid docosahexaenoic acid exerted a neuroprotective effect by efficiently rescuing the alterations revealed by our multidisciplinary approach. Together, this study provides strong evidence for the central and convergent role played by the synaptic microenvironment within the ALS spinal cord and highlights a potential therapeutic target that counteracts degeneration in a heterogeneous cohort of human motoneuron cultures.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a ALS
|2 Other
650 _ 7 |a Motoneuron
|2 Other
650 _ 7 |a Proteomics
|2 Other
650 _ 7 |a Spinal cord
|2 Other
650 _ 7 |a Synapse
|2 Other
650 _ 7 |a hiPSC
|2 Other
650 _ 7 |a Superoxide Dismutase-1
|0 EC 1.15.1.1
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: pathology
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: pathology
|2 MeSH
650 _ 2 |a Proteomics
|2 MeSH
650 _ 2 |a Superoxide Dismutase-1: genetics
|2 MeSH
650 _ 2 |a Motor Neurons: metabolism
|2 MeSH
700 1 _ |a Laszlo, Zsofia I.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Rajkumar, Sandeep
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Demir, Tugba
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Hindley, Nicole
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Lamont, Douglas J.
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Lehmann, Johannes
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Seidel, Mira
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Sommer, Daniel
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Franz-Wachtel, Mirita
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Barletta, Francesca
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Heumos, Simon
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Czemmel, Stefan
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Kabashi, Edor
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Ludolph, Albert
|0 P:(DE-2719)2812633
|b 14
|u dzne
700 1 _ |a Böckers, Tobias
|0 P:(DE-2719)2812855
|b 15
|u dzne
700 1 _ |a Henstridge, Christopher M.
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Catanese, Alberto
|0 P:(DE-2719)9001873
|b 17
773 _ _ |a 10.1007/s00401-023-02611-y
|0 PERI:(DE-600)1458410-4
|p 451 - 475
|t Acta neuropathologica
|v 146
|y 2023
|x 0001-6322
856 4 _ |u https://pub.dzne.de/record/259239/files/DZNE-2023-00740%20SUP.csv
856 4 _ |u https://pub.dzne.de/record/259239/files/DZNE-2023-00740%20SUP.ods
856 4 _ |u https://pub.dzne.de/record/259239/files/DZNE-2023-00740%20SUP.xls
856 4 _ |u https://pub.dzne.de/record/259239/files/DZNE-2023-00740%20SUP.xlsx
856 4 _ |u https://pub.dzne.de/record/259239/files/DZNE-2023-00740.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/259239/files/DZNE-2023-00740.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:259239
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2812633
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2812855
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)9001873
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-29
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-29
|w ger
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2023-10-21
920 _ _ |l yes
920 1 _ |0 I:(DE-2719)1910002
|k AG Böckers
|l Translational Protein Biochemistry
|x 0
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center Ulm
|l Clinical Study Center Ulm
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1910002
980 _ _ |a I:(DE-2719)5000077
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21